home / stock / gnftf / gnftf quote
Last: | $5.53 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $5.53 |
High: | $0 |
Low: | $0 |
Volume: | 15 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.53 | $0 | $5.53 | $0 | $0 | 15 | 07-19-2024 |
$5.53 | $0 | $5.53 | $0 | $0 | 5 | 07-05-2024 |
$5.53 | $0 | $5.53 | $0 | $0 | 150 | 06-28-2024 |
$5.53 | $0 | $5.53 | $0 | $0 | 3 | 06-24-2024 |
$5.53 | $0 | $5.53 | $0 | $0 | 55 | 06-10-2024 |
$5.53 | $5.5 | $5.53 | $5.53 | $5.5 | 1,440 | 06-07-2024 |
$5.13 | $0 | $5.13 | $0 | $0 | 15 | 06-05-2024 |
$5.13 | $0 | $5.13 | $0 | $0 | 75 | 06-04-2024 |
$5.13 | $0 | $5.13 | $0 | $0 | 60 | 06-03-2024 |
$5.13 | $5.13 | $5.13 | $5.13 | $5.13 | 200 | 05-29-2024 |
$2.95 | $2.95 | $2.95 | $2.95 | $2.95 | 150 | 04-15-2024 |
$2.98 | $0 | $2.98 | $0 | $0 | 3 | 04-08-2024 |
$2.98 | $2.98 | $2.98 | $2.98 | $2.98 | 800 | 03-05-2024 |
$3.45 | $0 | $3.45 | $0 | $0 | 10 | 02-20-2024 |
$3.45 | $0 | $3.45 | $0 | $0 | 10 | 01-30-2024 |
$3.45 | $0 | $3.45 | $0 | $0 | 1 | 01-02-2024 |
$3.45 | $3.45 | $3.45 | $3.45 | $3.45 | 1,201 | 01-01-2024 |
$3.45 | $3.45 | $3.45 | $3.45 | $3.45 | 1,201 | 12-29-2023 |
$3.03 | $0 | $3.03 | $0 | $0 | 29 | 12-13-2023 |
$3.03 | $3.03 | $3.03 | $3.03 | $3.03 | 1,500 | 12-08-2023 |
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...